ECTRIMS 2023 | Assessing predictors of relapse in MOGAD patients

Torge Rempe, MD, PhD, University of Florida College of Medicine, Gainesville, FL, discusses a multicenter, retrospective study aimed at evaluating predictors for relapse in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). The research examined 541 charts, culminating in a cohort of 76 patients. Key findings revealed that approximately two-thirds relapsed, with 19% experiencing their first relapse five years after the initial episode. Potential predictors included pediatric onset, Hispanic ethnicity, clinical syndrome of meningoencephalitis, high pleocytosis, and elevated anti-MOG titers. The study also explored disease-modifying therapies, noting IVIg as a promising maintenance therapy. However, the retrospective design presented limitations, including heterogeneous data and potentially inadequate follow-up periods. Further research is imperative to validate the identified predictors. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.